Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. With advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected.~2. ECOG performance status of 0 or 1.~3. Subjects must have at least one measurable lesion.~4. Patients with life expectancy ≥ 3 months.~5. Subject must have adequate organ function.~6. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for six months after last study drug administration.~Exclusion Criteria:~1. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.~2. Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded.~3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.~4. Known history of HIV infection.~5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) positive or Hepatitis C virus (HCV) antibody positive.~6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.~7. Known history of alcoholism or drugs abuse.~For more information regarding trial participation, please contact at cstonera@cstonepharma.com

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CS1001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).